




15






















21


THE FRITSMA	Example: Thrombophilia Profile					
FACTOR Your		Assay	Patient	RI		
Interactive Hemostasis Resource		60 YOA male, DVT, 3 Weeks Coumadin				
		Protein C activity	35%	>70%		
		Protein S activity	39%	>65%		
		Antithrombin activity	87%	78-126%		
		APCR	2.4	>1.8		
		Factor V Leiden	Wild-type	Wild-type		
		PTT-LA	39 s	30–40 s		
		Protein C & S are vitamin K-dependent coag control proteins.				
	The	Double heterozygote? Increase Coumadin? Start heparin? Consult with the lab? Fritms Factor			23	






Barbard Stranger Stranger







	Assay
HGB 14.2 g/dL 13.5-	is HGB
PTT 59 s 25	PTT
PT 12.4 s 9.8	PT
PLT count 310,000/µL 250-4	PLT count
Fibrinogen 270 mg/dL 150-4	Fibrinogen
o bleeding Hx, surgeon postpones procedure	No bleeding Hx,
Fibrinogen 270 mg/dL 150-4	Fibrinogen No bleeding Hx, • Heparin pres • Repeat PTT


Assay	Patient	RI		
HGB	14.2 g/dL	13.5–15.6 g/dL		
PTT	59 s	25–35 s		
PT	12.4 s	9.8–12.6 s		
TT	18.2 s	<21 s		
PLT count	310,000/µL	250-450,000/µl		
Fibrinogen	270 mg/dL	150-400 mg/dL		
No bleedir	No bleeding Hx, surgeon postpones procedure			
deficiency, coagula	d PTT may indicate ation factor inhibitor mal TT indicates no	or lupus		








THE FRITSMA FACTOR	LA Profile: How About This?							
Your	Assay	Result	RI	Comment				
Hemostasis Resource	PTT-LA	47.9 s	30–40 s	Confirms PTT				
Resource	PTT-LA/control 1:1	38.5 s	Control 34.5 s	Possible LA				
	Staclot LA kit	12 s	> 8s correction	Confirms LA				
	DRVVT	52.5 s	35–45 s	Possible LA				
	DRVVT confirm	1.4 ratio	> 1.2 correction	Confirms LA				
	Or: "Patient plasma tested using LA-sensitive PTT reagent and dilute Russell viper venom reagent, both prolonged, both corrected by high phospholipid neutralization reagent, confirming LA. No bleeding risk, may indicate thrombosis risk if LA is chronic. Repeat after 12 weeks to determine persistence."							
	Quesada AE, Jabcuga CE, Nguyen A, et al. Interpretation of coagulation test results using a web-based reporting system. Lab Medicine 2014;45:343–56. The Fittame Factor 30							







**American Society for Clinical** CTOR Laboratory Science Don't order a factor V Leiden (FVL) mutation assay as the initial test to identify a congenital cause for a thrombotic event. First, order a phenotypic activated protein C resistance (APCR) ratio assay. Avoid using hemoglobin to evaluate patients for iron deficiency in susceptible populations. Instead use ferritin. Do not transfuse red blood cells as the sole intervention for expansion of circulatory volume unless deemed necessary for patients experiencing severe hemorrhage. Choosing **Wisely** 


33







32













The Dallas Intervention CTOR Investigate as outpatients if they met the criteria (young age, unprovoked event) ≥2 weeks following D/C of anticoagulation. Hemostasis service communicated with clinicians to cancel testing that was deemed inappropriate. Intervention reduced total orders from 87/m to 5/m. - Reduced inpatient orders by 90%

39





40

